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Additive effect of dabigatran and high-dose aspirin in 
the development of haemorrhagic pleural effusion in 
a patient with tuberculous pleuritis
Case Report
Abstract
Tuberculous pleuritis can rarely cause haemorrhagic pleural effusion. Dabigatran etexilate can have an additive effect on increasing the 
risk of  haemorrhage. Aspirin cannot cause major haemorrhage, but in the elderly it can cause gastrointestinal bleeding via ulceration 
of  the gastrointestinal mucosa. We report here the case of  a 77-year-old male who presented to the hospital with a 2-month history 
of  progressive dyspnoea. He had been taking dabigatran etexilate (220 mg) and high-dose acetylsalicylic acid (aspirin; 300 mg) daily for 
chronic atrial fibrillation. A chest X-ray revealed a moderately sized right pleural effusion confirmed by a computed tomography scan, 
which also showed bronchiectasis of  both lungs. Dabigatran was discontinued and aspirin was decreased to the minimal therapeutic 
dose of  100 mg before thoracentesis was performed. Lymphocyte-predominant (50%) haemorrhagic fluid of  500 ml was drained, 
positive for acid-fast bacilli smear and polymerase chain reaction of  Mycobacterium tuberculosis. A chest tube was placed and an 
additional 1250 ml of  haemorrhagic exudate drained out. We treated the patient with a routine regimen of  antituberculous medication 
and the infection resolved without complications other than the bronchiectasis present before treatment. We think that the combination 
of  dabigatran etexilate and high doses of  aspirin increased the risk of  pleural haemorrhage in this patient with tuberculous pleuritis.
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Case report
A 77-year-old male non-smoker presented to the outpatient 
unit of  the Chest Disease Department at Ankara University 
Hospital with a 2-month history of  progressive dyspnoea 
in September 2014. His past medical history was significant 
for atrial fibrillation, diabetes mellitus type 2, coronary artery 
disease, hypertension, hyperlipidaemia, and congestive heart 
failure. He had taken dabigatran etexilate 110 mg orally 
twice daily for the previous 2 months. His other medication 
consisted of  metoprolol 50 mg/day, atorvastatin 20 mg/day, 
metformin 1000 mg twice daily, and acetylsalicylic acid 
(aspirin) 300 mg/day. The patient’s vital signs were normal 
except for an irregular pulse rate of  130 beats/min. His 
body mass index (BMI) was 17.5 kg/m2. He had decreased 
breath sounds in the right lower lung field, with dullness to 
percussion and bilateral coarse crackles scattered throughout 
the lung fields.
An electrocardiogram showed atrial fibrillation. On 
admission his white blood cell count was 9.2×103/mm3 
(normal range: 4.0–12.4×103), haemoglobin was 12.7 g/
dl (normal range: 11.6–15.2), platelet count was 295×103/
mm3 (normal range: 141–320×103), haematocrit was 37% 
(normal range: 41–50%), blood glucose was 115 mg/dl 
(normal range: 100–110), blood urea nitrogen was 19 mg/dl 
(normal range: 7–20), serum creatinine 0.84 mg/dl (normal 
range: 0.7–1.2) with an estimated creatinine clearance of  89 
ml/min (using the Modification of  Diet in Renal Disease 
equation), the prothrombin time (PT) was 20 s (normal 
range: 11–13) and activated partial thromboplastin time 
(aPTT) was 52.2 s (normal range: 25–36) with international 
normalised ratio (INR) level of  2.6 (normal range: 1–1.3). 
A chest X-ray revealed a moderate right pleural effusion 
(Figure 1A). A chest computed tomogram showed right 
pleural thickening and bilateral lower lobe bronchiectasis 
(Figure 1B). Echocardiography revealed left ventricular 
systolic dysfunction with a 45% ejection fraction. 
Aspirin level was reduced to 100 mg/day, a safe limit for 
bleeding risk, and dabigatran etexilate was discontinued 
for 3 days to decrease PT and aPTT levels and INR within 
the normal range (12 s, 35 s and 1.3, respectively). Flexible 
bronchoscopy (FB) was performed revealing coarse pleated 
bronchial mucosa, haemorrhage with FB touch, and smooth 
outer compression at the right lower lobe. Haemorrhagic 
fluid (500 ml) was initially sampled by thoracentesis from the 
right pleural space (Figure 1C,D). In the same session, using 
ultrasound guidance a chest tube was placed to drain all the 
haemorrhagic material, along with a pleural biopsy revealing 
granulomatous inflammation. Within 48 h, 1250 ml of  
haemorrhagic accumulation was seen on the drainage system 
until it was removed (Figure 1E). Cytological examination 
revealed excessive erythrocytes and lymphocytes (50% 
excess), but no malignant cells were seen. The haematocrit 
was 18.5%, and there was no growth of  microorganisms on 
common cultures.
As the diagnosis of  tuberculous pleuritis (TP) was proven 
via smear and polymerase chain reaction (PCR) positivity for 
acid-fast bacilli of  the fluid, four-drug oral antituberculous 
therapy including rifampicin, isoniazid, ethambutol, and 
pyrazinamide was commenced at the fifth hospital day and 
was well tolerated. Prophylactic bemiparin sodium 5000 
IU/day subcutaneously was given until the end of  the 
treatment instead of  oral anticoagulants to prevent probable 
thrombosis.
Dyspnoea was resolved in the first hospital week and the 
patient was discharged on the 10th hospital day, with only 
right costophrenic angle blunting without any recurrence. 
Antituberculous therapy was continued for 6 months. He 
stayed alive for 5 years then passed away from cardiac reasons.
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Discussion
Exudative pleural effusion with pleural lymphocytosis 
(suggestive for tuberculosis), acid-fast bacilli stain, PCR 
evaluation, and histopathological examination led us to a 
definitive diagnosis of  TP. As haemorrhagic effusion is 
known as unlikely in TP in clinical practice1, the cause of  a 
higher amount of  pleural haemorrhagic effusion was needed 
to be explained at the first stage in this patient.
First, the patient was taking two major drugs that could 
contribute to haemorrhage, aspirin (300 mg/day) and 
dabigatran etexilate (110 mg, twice daily). Although aspirin 
can act as a prostaglandin synthetase inhibitor blocking 
aggregation of  the platelets, it is not recorded as a causative 
agent of  pleural haemorrhagic effusion by itself  at any dose 
in the literature in English2. Furthermore, its cessation is not 
recommended before bronchoscopy as it cannot increase 
the risk of  bleeding3,4. However, a higher dose (300 mg) of  
aspirin can cause or contribute to major bleeding occurring 
first in the gastrointestinal system (GIS) followed by the 
cerebrovascular system5. In this case, high-dose aspirin may 
have contributed to the accumulation of  haemorrhagic 
effusion, but if  so, there should also have been bleeding in 
the GIS or cerebrovascular system in addition to the pleural 
space. Therefore, the absence of  these effects suggested that 
this drug might not be the only cause of  haemorrhage. The 
aspirin dose was reduced to 100 mg before the procedures 
and no fresh haemorrhage related to these procedures was 
observed. 
Second, the patient was given dabigatran etexilate as the only 
oral antithrombin agent, which is one of  the direct factor 
Xa inhibitors that prevents prothrombin from cleaving 
to thrombin. It binds directly to factor Xa, rather than 
enhancing the activity of  antithrombin, as is done by heparin. 
Acute bleeding episodes, such as intracranial haemorrhage, 
haemopericardium, and diffuse alveolar haemorrhage have 
been reported to be associated with or worsening from 
use of  dabigatran etexilate6. Two similar cases with non-
valvular atrial fibrillation have been reported in patients of  
72 and 83 years of  age who developed haemothorax and 
were receiving 110 mg of  dabigatran twice daily. These 
patients were managed by cessation of  the drug and a large 
amount of  chest drainage (1400 and 2500 ml, respectively). 
It is claimed that age or renal impairment could play some 
role in those with increased bleeding risk6. Therefore, it has 
been suggested that plasma levels should be checked and the 
dose should be individualized according to the plasma level, 
otherwise, there is a risk of  complication with bleeding 15% 
higher than the normal population. 
Combining aspirin with novel anticoagulants does not provide 
additional benefit in stroke reduction and is associated with 
an increased risk of  bleeding complications. Therefore, care 
should be taken to determine if  and when the benefits of  
concomitant aspirin outweigh the risks in patients with atrial 
fibrillation already on oral anticoagulants7. In a large study, 
high dose (300 mg) of  aspirin combined with higher doses 
(300 mg) of  dabigatran can contribute to major bleeding 
events. However, lower doses (50–150 mg) of  dabigatran 
cannot prevent thromboembolic episodes even with aspirin8. 
We think that in this case, adding dabigatran in the course of  
aspirin can be a major contributing factor when taking into 
account prolonged PT, aPTT, and INR which were hardly 
Figure 1. (A) Chest X-ray with right-sided pleural fluid. (B) Thorax computed tomogram showed pleural fluid and 
bronchiectasis on the right lower lobe. (C,D) Haemorrhagic pleural fluid seen during aspiration. (E) Chest X-ray after 
drainage of the fluid.
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becoming normal in 3 days of  cessation. Since dabigatran 
with a long half-life (12–17 h) is given twice daily in advanced 
patient age, plasma accumulation may cause haemothorax 
despite borderline-normal kidney functions.
This patient was old, had diabetes, and was malnourished 
(low BMI). These are all risk factors for active tuberculosis 
disease. TP can be seen with or without pulmonary 
parenchymal tuberculosis. In this patient, there was no 
finding of  tuberculosis affecting pulmonary parenchymal 
tissue reflecting active disease. However, pleural effusion 
was high, causing dyspnoea. Pleural fluid in TP is usually 
straw-coloured exudate, or rarely slightly bloody, usually 
without exceeding one- to two-thirds of  the hemithorax9. 
On the contrary, several haemorrhagic types have been 
reported in the literature10-12. In a case report, it was stated 
massive haemorrhagic pleural effusion was extremely rare. 
Pleural biopsy has the best diagnostic yield for TP and 
as it was defined as a protean disease (having a thousand 
faces), it should always be in the differential diagnosis of  
a patient with a lymphocytic pleural exudate, whether it is 
haemorrhagic or not, small or massive10. In large reviews, TP 
was complicated with empyema, fibrothorax, chylothorax, 
and other possibilities; however, haemorrhagic effusion can 
be described in only 11%11,12. In a study, only 9% of  the 
patients (n=100) had haemorrhagic effusion whereas 90% 
had straw-coloured effusion13. Therefore, it is imperative to 
investigate drugs that contribute to haemorrhagic effusion.
Pleural drainage was also recommended to relieve dyspnoea 
and avoid complications8-12. In this case, the fluid probably 
exceeded two-thirds of  the hemithorax and/or would 
become complicated had it not been drained.
To conclude, physicians should be aware of  the 
antiaggregant/anticoagulant drugs used by the patient or 
infectious disease such as tuberculosis, especially in cases 
with pleural haemorrhagic effusion.
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